AKBA Stock Summary and Trading Ideas (Akebia Therapeutics | NASDAQ:AKBA)

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Akebia Therapeutics trades on the NASDAQ stock market under the symbol AKBA.

As of February 11, 2026, AKBA stock price climbed to $1.55 with 4,371,895 million shares trading.

AKBA has a beta of 0.35, meaning it tends to be less sensitive to market movements. AKBA has a correlation of 0.01 to the broad based SPY ETF.

AKBA has a market cap of $410.97 million. This is considered a Small Cap stock.

Last quarter Akebia Therapeutics reported $59 million in Revenue and $.00 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.02.

In the last 3 years, AKBA traded as high as $4.08 and as low as $.49.

The top ETF exchange traded funds that AKBA belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.

AKBA has underperformed the market in the last year with a return of -26.2%, while the SPY ETF gained +15.5%. In the last 3 month period, AKBA fell short of the market, returning -14.4%, while SPY returned +1.6%. However, in the most recent 2 weeks AKBA has outperformed the stock market by returning +6.9%, while SPY returned -0.5%.

AKBA support price is $1.45 and resistance is $1.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKBA shares will trade within this expected range on the day.